ibudilast has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oskarsson, B | 1 |
| Maragakis, N | 1 |
| Bedlack, RS | 1 |
| Goyal, N | 1 |
| Meyer, JA | 1 |
| Genge, A | 1 |
| Bodkin, C | 1 |
| Maiser, S | 1 |
| Staff, N | 1 |
| Zinman, L | 1 |
| Olney, N | 1 |
| Turnbull, J | 1 |
| Brooks, BR | 1 |
| Klonowski, E | 1 |
| Makhay, M | 1 |
| Yasui, S | 1 |
| Matsuda, K | 2 |
| Chen, Y | 1 |
| Wang, H | 1 |
| Ying, Z | 1 |
| Gao, Q | 1 |
| Babu, S | 1 |
| Hightower, BG | 1 |
| Chan, J | 1 |
| Zürcher, NR | 1 |
| Kivisäkk, P | 1 |
| Tseng, CJ | 1 |
| Sanders, DL | 1 |
| Robichaud, A | 1 |
| Banno, H | 1 |
| Evora, A | 1 |
| Ashokkumar, A | 1 |
| Pothier, L | 1 |
| Paganoni, S | 1 |
| Chew, S | 1 |
| Dojillo, J | 1 |
| Gudesblatt, M | 1 |
| Berry, JD | 1 |
| Cudkowicz, ME | 1 |
| Hooker, JM | 1 |
| Atassi, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis[NCT04057898] | Phase 2/Phase 3 | 230 participants (Anticipated) | Interventional | 2020-05-28 | Recruiting | ||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ibudilast and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Neurodegenerative Diseases; Pyridines; Q | 2021 |
2 other studies available for ibudilast and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy.
Topics: Amyotrophic Lateral Sclerosis; Autophagosomes; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Tran | 2020 |
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Humans; Pyridines | 2021 |